Valrubicin Intravesical Solution

For Intravesical Use Only.  Do NOT administer by intravenous or intramuscular routes.

Valrubicin intravesical solution is recommended at a dose of 800 mg administered intravesically once a week for six weeks. Delay administration at least two weeks after transurethral resection and/or fulguration [see Warnings and Precautions (5.2, 5.3)].

Handle and dispose of valrubicin intravesical solution in a manner consistent with other cytotoxic drugs.¹ The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug.

Valrubicin intravesical solution contains polyoxyl castor oil, which has been known to cause leaching of di(2-ethylhexyl) phthalate (DEHP) a hepatotoxic plasticizer, from polyvinyl chloride (PVC) bags and intravenous tubing. Valrubicin intravesical solution should be prepared and stored in glass, polypropylene, or polyolefin containers and tubing. It is recommended that non-DEHP containing administration sets, such as those that are polyethylene-lined, be used.

Valrubicin intravesical solution is a clear red solution. Visually inspect for particulate matter and discoloration prior to administration. At temperatures below 4°C (39°F), polyoxyl castor oil may begin to form a waxy precipitate. If this happens, the vial should be warmed in the hand until the solution is clear. If particulate matter is still seen, do not administer valrubicin intravesical solution.

For each instillation, slowly allow four 5 mL vials (200 mg valrubicin/5 mL vial) to warm to room temperature, but do not heat. Withdraw 20 mL of valrubicin intravesical solution from the four vials and dilute with 55 mL of 0.9% Sodium Chloride Injection, USP to provide 75 mL of a diluted valrubicin intravesical solution. Valrubicin intravesical solution diluted in 0.9% Sodium Chloride Injection, USP for administration is stable for 12 hours at temperatures up to 25°C (77°F). Since compatibility data are not available, do not mix valrubicin intravesical solution with other drugs.

Insert a urethral catheter into the patient's bladder under aseptic conditions, drain the bladder, and instill the diluted 75 mL valrubicin intravesical solution slowly via gravity flow over a period of several minutes. Withdraw the catheter and retain valrubicin intravesical solution in the bladder for two hours before voiding. At the end of two hours, all patients should void. Some patients may be unable to retain the drug for the full two hours. Instruct patients to maintain adequate hydration following valrubicin intravesical solution treatment [see Patient Counseling Information (17)].

Inform patients that valrubicin intravesical solution has been shown to induce complete response in only about 1 in 5 patients with BCG-refractory CIS, and that delaying cystectomy could lead to development of metastatic bladder cancer, which is lethal. The exact risk of developing metastatic bladder cancer from such a delay may be difficult to assess [see Clinical Studies (14)] but increases the longer cystectomy is delayed in the presence of persisting CIS. If there is not a complete response of CIS to treatment after 3 months or if CIS recurs, reconsider cystectomy.

Evaluate the bladder before the intravesical instillation of drug and do not administer valrubicin intravesical solution to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised [see Contraindications (4)]. In case of bladder perforation, delay the administration of valrubicin intravesical solution until bladder integrity has been restored. One patient with a perforated bladder who received 800 mg of valrubicin intravesical solution intravesically developed severe leukopenia and neutropenia approximately two weeks after drug administration [see Clinical Pharmacology (12.3)].

To avoid systemic exposure to valrubicin intravesical solution for the patients undergoing TURB, evaluate the status of the bladder before the intravesical instillation of drug. Delay administration at least two weeks after transurethral resection and/or fulguration.

Use valrubicin intravesical solution with caution in patients with severe irritable bladder symptoms. Bladder spasm and spontaneous discharge of the intravesical instillate may occur; clamping of the urinary catheter is not advised.

Based on findings in animal studies and its mechanism of action, valrubicin intravesical solution can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1 and 12.3)]. In animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intravesical dose caused embryo-fetal malformations and increased resorptions. Advise females who might become pregnant of the potential risk to a fetus.

Advise females of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 6 months following the final dose [see Use in Specific Populations (8.1 and 8.3)].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of valrubicin intravesical solution was assessed in 230 patients with transitional cell carcinoma of the bladder, including 205 patients who received multiple weekly doses. One hundred seventy-nine of the 205 patients received the approved dose and schedule of 800 mg weekly for multiple weeks.

Approximately 84% of patients who received intravesical valrubicin intravesical solution in clinical studies experienced local adverse reactions. The local adverse reactions associated with valrubicin intravesical solution usually occur during or shortly after instillation and resolve within 1 to 7 days after the instillate is removed from the bladder. Seven out of 143 patients (5%) who were scheduled to receive six doses of valrubicin intravesical solution failed to receive all of the planned doses because of the occurrence of local bladder symptoms.

TABLE 1 displays the frequency of the local adverse reactions at baseline and during treatment among 179 patients who received 800 mg doses of valrubicin intravesical solution in a multiple-cycle treatment regimen.

TABLE 2 displays the adverse reactions other than local bladder symptoms that occurred in 1% or more of the 230 patients who received at least one dose of valrubicin intravesical solution in a clinical trial.

Adverse reactions other than local reactions that occurred in less than 1% of the patients who received valrubicin intravesical solution intravesically in clinical trials are listed below.

1. Digestive System: Tenesmus
   Metabolic and Nutritional: Nonprotein nitrogen increased
   Skin and Appendages: Pruritus
   Special Senses: Taste loss
   Urogenital System: Local skin irritation, poor urine flow, and urethritis

Risk Summary

Based on findings in animal studies and its mechanism of action, valrubicin intravesical solution can cause fetal harm when administered to a pregnant females [see Clinical Pharmacology (12.1 and 12.3)]. There are no available data in pregnant females to inform the drug-associated risk. In animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intravesical dose caused embryo-fetal malformations and increased resorptions [see Data]. Advise females who are or might become pregnant of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Daily intravenous administration of valrubicin to pregnant rats during the period of organogenesis at doses ≥ 12 mg/kg (about 0.2 times the recommended human intravesical dose on a mg/m² basis) was embryo-fetal toxic and teratogenic. Administration of 12 mg/kg resulted in fetal malformations. A dose of 24 mg/kg (about 0.3 times the recommended human intravesical dose on a mg/m² basis) caused numerous, severe alterations in the skull and skeleton of the developing fetuses. This dose also caused an increase in fetal resorptions and a decrease in viable fetuses.

Risk Summary

There are no data on the presence of valrubicin or its metabolites in human milk, the effects of valrubicin on the breast-fed infant, or its effects on milk production. Because of the potential for serious adverse reactions in breast-fed infants from valrubicin, advise a lactating female not to breastfeed during treatment with valrubicin intravesical solution and for 2 weeks after the final dose.

Contraception

Females

Valrubicin intravesical solution can cause fetal harm when administered to a pregnant female. Advise females of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 6 months after the final dose [see Use in Specific Populations (8.1)].

Males

Based on genotoxicity findings, advise men with female partners of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 3 months following the final dose [see Non Clinical Toxicology (13.1)]

Infertility

Males

Studies of the effects of valrubicin intravesical solution on human male or female fertility have not been done. Based on findings in animal studies, valrubicin intravesical solution may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)].

Safety and effectiveness in pediatric patients have not been established.

Because carcinoma in situ of the bladder generally occurs in older individuals, 85% of the patients enrolled in the clinical studies of valrubicin intravesical solution were more than 60 years of age (49% of the patients were more than 70 years of age). In the primary efficacy studies, the mean age of the population was 69.5 years. There are no specific precautions regarding use of valrubicin intravesical solution in geriatric patients who are otherwise in good health.

Valrubicin is an anthracycline that affects a variety of interrelated biological functions, most of which involve nucleic acid metabolism. In cells, it inhibits the incorporation of nucleosides into nucleic acids, causes chromosomal damage, and arrests the cell cycle in G₂. Although valrubicin does not bind strongly to DNA, valrubicin metabolites interfere with the normal DNA breaking-resealing action of DNA topoisomerase II.

When 800 mg valrubicin intravesical solution was administered intravesically to patients with carcinoma in situ, valrubicin intravesical solution penetrated into the bladder wall. The mean total anthracycline concentration measured in bladder tissue exceeded the levels causing 90% cytotoxicity to human bladder cells cultured in vitro. During the two-hour dose-retention period, the metabolism of valrubicin intravesical solution to its major metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol in bladder tissue was negligible. After retention, the drug was almost completely excreted by voiding the instillate. Mean percent recovery of valrubicin intravesical solution, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samples from six patients was 98.6%, 0.4%, and 99.0% of the total administered drug, respectively. During the two-hour dose-retention period, only nanogram quantities of valrubicin intravesical solution were absorbed into the plasma. N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol were measured in blood.

Total systemic exposure to anthracyclines during and after intravesical administration of valrubicin intravesical solution is dependent upon the condition of the bladder wall. The mean AUC_{0-6 hours} (total anthracyclines exposure) for an intravesical dose of 900 mg of valrubicin intravesical solution administered 2 weeks after transurethral resection of bladder tumors (n=6) was 78 nmol/L•hr. In patients receiving 800 mg of valrubicin intravesical solution 5 to 51 minutes after typical (n=8) and extensive (n=5) TURB tumors, the mean AUC_{0-6 hours} values for total anthracyclines were 409 and 788 nmol/L•hr, respectively. The AUC_{0-6 hours} total exposure to anthracyclines was 18,382 nmol/L•hr in one patient who experienced a perforated bladder following a transurethral resection that occurred 5 minutes before administration of an intravesical dose of 800 mg of valrubicin intravesical solution. Administration of a comparable intravenous dose of valrubicin intravesical solution (600 mg/m²; n=2) as a 24-hour infusion resulted in an AUC_{0-6 hours} for total anthracyclines of 11,975 nmol/L•hr. These results are shown in FIGURE 2.

FIGURE 2. Comparison of Mean AUC_0-6 hours in Valrubicin Intravesical Solution Clinical Studies (N=number of patients)

The carcinogenic potential of valrubicin has not been evaluated.

In vitro, valrubicin was mutagenic in the bacterial reverse mutation (Ames) assay and clastogenic in the chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells.

Studies in animals evaluating the effects of valrubicin on male or female fertility have not been conducted. Based on effects on male reproductive organs in general toxicology studies in dogs with intravesical instillation, valrubicin may impair fertility in male patients. When instilled into the bladder of male dogs weekly for 6 weeks, valrubicin caused mild to moderate atrophy of the prostate with inflammation, diffuse decrease in acinar size, epithelial changes. It also caused testicular degeneration, marked germ cell depletion, spermatid giant cells and karyomegaly.